UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy

P Diez¹, G G Hanna², K L Aitken³, N van As⁴, A Carver⁵, R J Colaco⁶, J Conibear⁷, E M Dunne⁸, D J Eaton⁹, K N Franks¹⁰, J S Good¹¹, S Harrow¹², P Hatfield¹⁰, M A Hawkins¹³, S Jain², F McDonald⁴, R Patel¹, T Rackley¹⁴, P Sanghera¹¹, A Tree³, L Murray¹⁵

Affiliations

¹ Radiotherapy Physics, National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Cancer Centre, Northwood, UK.
² Belfast Health and Social Care Trust, Belfast, UK; Queen's University Belfast, Belfast, UK.
³ Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; Institute of Cancer Research, London, UK.
⁴ Institute of Cancer Research, London, UK; Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Chelsea, London, UK.
⁵ Department of Medical Physics, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK.
⁶ Department of Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UK.
⁷ Radiotherapy Department, Barts Cancer Centre, London, UK.
⁸ Department of Clinical Oncology, Guys and St Thomas' NHS Foundation Trust, London, UK.
⁹ Radiotherapy Physics, National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Cancer Centre, Northwood, UK; Department of Medical Physics, Guys and St Thomas' NHS Foundation Trust, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
¹⁰ Department of Clinical Oncology, Leeds Cancer Centre, St James's University Hospitals, Leeds, UK.
¹¹ Department of Clinical Oncology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK.
¹² Department of Clinical Oncology, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
¹³ Department of Medical Physics and Biomechanical Engineering, University College London, London, UK; Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁴ Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK.
¹⁵ Department of Clinical Oncology, Leeds Cancer Centre, St James's University Hospitals, Leeds, UK; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK. Electronic address: L.J.Murray@leeds.ac.uk.

PMID: 35272913
DOI: 10.1016/j.clon.2022.02.010

UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy

P Diez et al. Clin Oncol (R Coll Radiol). 2022 May.

. 2022 May;34(5):288-300.

doi: 10.1016/j.clon.2022.02.010. Epub 2022 Mar 7.

Authors

Affiliations

¹ Radiotherapy Physics, National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Cancer Centre, Northwood, UK.
² Belfast Health and Social Care Trust, Belfast, UK; Queen's University Belfast, Belfast, UK.
³ Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; Institute of Cancer Research, London, UK.
⁴ Institute of Cancer Research, London, UK; Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Chelsea, London, UK.
⁵ Department of Medical Physics, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK.
⁶ Department of Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UK.
⁷ Radiotherapy Department, Barts Cancer Centre, London, UK.
⁸ Department of Clinical Oncology, Guys and St Thomas' NHS Foundation Trust, London, UK.
⁹ Radiotherapy Physics, National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Cancer Centre, Northwood, UK; Department of Medical Physics, Guys and St Thomas' NHS Foundation Trust, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
¹⁰ Department of Clinical Oncology, Leeds Cancer Centre, St James's University Hospitals, Leeds, UK.
¹¹ Department of Clinical Oncology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK.
¹² Department of Clinical Oncology, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
¹³ Department of Medical Physics and Biomechanical Engineering, University College London, London, UK; Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁴ Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK.
¹⁵ Department of Clinical Oncology, Leeds Cancer Centre, St James's University Hospitals, Leeds, UK; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK. Electronic address: L.J.Murray@leeds.ac.uk.

PMID: 35272913
DOI: 10.1016/j.clon.2022.02.010

Abstract

The use of stereotactic ablative radiotherapy (SABR) in the UK has expanded over the past decade, in part as the result of several UK clinical trials and a recent NHS England Commissioning through Evaluation programme. A UK SABR Consortium consensus for normal tissue constraints for SABR was published in 2017, based on the existing literature at the time. The published literature regarding SABR has increased in volume over the past 5 years and multiple UK centres are currently working to develop new SABR services. A review and update of the previous consensus is therefore appropriate and timely. It is hoped that this document will provide a useful resource to facilitate safe and consistent SABR practice.

Keywords: Constraints; OAR; SABR; SBRT; normal tissue; stereotactic radiotherapy.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy

Affiliations

UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous